aurora canabis inc nasdaq

The deep research logic is organized as follows: 

Okay, let's tackle this question about Aurora Cannabis Inc. on NASDAQ. The user is asking specifically about ACB on NASDAQ, so I need to focus on the relevant data and references provided.

First, I'll check the references. There's a mix of data points here. The user mentioned "AUR Closing Price on NASDAQ" in reference 1, which shows AUR at $6.16 as of 2025-08-08. But the user is asking about Aurora Cannabis, which is ACB, not AUR. Wait, there's a potential confusion here. Let me make sure I'm looking at the right stock symbols.

Looking at reference 6, the query is "Aurora Cannabis Inc NASDAQ stock symbol," and the result shows ACB with a last price of $4.48 and a 6.41% change. Also, reference 17 clarifies the stock tickers: ACB is Aurora Cannabis, and AUR is Aurora Innovation. So the user might be mixing up the two companies. I need to address that to avoid confusion.

The user's question is about Aurora Cannabis Inc. on NASDAQ, so I should focus on ACB. Let's gather the latest data. Reference 12 provides the closing price for ACB on 2025-08-11 as $4.48. That's the most recent data point. The last change is 6.41%, which is a significant increase. I should note that in the answer.

Next, looking at the financial results. Reference 2 mentions the first quarter 2026 results announced on 2025-08-06. The key points here are the revenue growth, adjusted EBITDA, and cash position. The revenue increased by 17% YoY to $98 million, and adjusted EBITDA rose 209% to $10.8 million. The company also has $186 million in cash and a debt-free cannabis business, which is a strong financial position. However, there's a net loss of $14.7 million, which is a concern. The user might be interested in the profitability and cash flow situation.

There's also a mention of a class-action investigation in reference 4, which could impact investor sentiment. The stock dropped 20% on June 18, 2025, due to this. The user might want to know about the risks involved. Additionally, the company's international expansion, especially in medical cannabis markets like Germany and Poland, is a positive factor. The revenue from international markets increased by 85% YoY, which shows growth potential.

The user might be considering investing in ACB, so I should highlight both the positives and the risks. The positives include strong revenue growth, improving margins, and a solid cash position. The risks are the ongoing legal issues, net losses, and high volatility (beta of 1.47 and historical volatility of 52%). The recent stock price movement (6.41% increase) could indicate market reaction to the Q1 results, but the user should be cautious about the short-term volatility.

Also, the user might be confused between ACB and AUR since both are listed on NASDAQ. I should clarify the stock symbols and their respective companies to prevent any mix-up. Reference 17 explicitly differentiates between the two, so that's a good point to include.

Putting it all together, the answer should start with the current stock price and recent performance, then delve into the financial results, market position, risks, and conclude with an investment takeaway. Make sure to cite the references properly and include the visualization for the closing price query.

### 🌿 **Aurora Cannabis Inc. (ACB) on NASDAQ: Key Insights & Analysis** 🌿

#### 🌟 **Conclusion** 🌟
Aurora Cannabis Inc. (NASDAQ: ACB) is positioned as a leading player in the global medical cannabis market, with **robust revenue growth**, **improved profitability**, and a **strong balance sheet**. However, the stock faces **short-term risks** due to regulatory uncertainties, legal challenges, and high volatility. Recent financial results highlight **operational progress**, but the company remains **profit-challenged** with a net loss in Q1 2026.

---

### 📊 **Key Data & Analysis** 📊

#### 1. **Current Stock Performance**
- **Closing Price**: $4.48 as of August 11, 2025 .
- **Recent Price Action**: A **6.41% increase** in the last trading session, reflecting market optimism post-Q1 2026 earnings .
- **Market Capitalization**: Not explicitly provided, but the stock’s **beta of 1.47** indicates higher volatility compared to the broader market .

| Metric | Value | Implication |
|-----------------------|----------------|--------------------------------------|
| Closing Price [2025-08-11] | $4.48 | Recent bullish sentiment post-earnings |
| 52-Week Range | Not provided | High volatility (52% historical) |
| Cash Position | $186M | Strong liquidity for expansion |

|code|Ticker|Name|Date|Closing Price|market_code|
|---|---|---|---|---|---|
|NDAQ|NDAQ.O|Nasdaq|20250808|96.85|185|
|AUR|AUR.O|Aurora Innovation|20250808|6.16|185|

---

#### 2. **Financial Results (Q1 2026)**
- **Revenue**: $98.0M (17% YoY growth) .
- **Adjusted EBITDA**: $10.8M (209% YoY increase) .
- **Net Loss**: $14.7M (vs. $6.2M profit in Q1 2025) .
- **Free Cash Flow**: $9.2M (42% YoY growth) .

| Metric | Q1 2026 vs. Q1 2025 | Key Driver |
|-----------------------|-----------------------|--------------------------------------|
| Revenue Growth | +17% | Medical cannabis expansion |
| EBITDA Margin | 11% (vs. 4% YoY) | Cost optimization |
| Net Loss | -337% | One-time charges |

---

#### 3. **Market Position & Risks**
- **Market Share**: Aurora leads in **global medical cannabis**, with 37% YoY revenue growth in this segment .
- **Regulatory Risks**: Ongoing **class-action investigation** (Pomerantz LLP) and **inventory misstatements** reported in Q1 2026 .
- **Competition**: Faces pressure from peers like Canopy Growth (CGC) and Tilray (TLRY) .

| Risk Factor | Impact | Mitigating Factor |
|-----------------------|-----------------------|--------------------------------------|
| Legal Challenges | Stock volatility | Strong cash reserves ($186M) |
| Profitability | Net loss | High-margin medical cannabis |
| Market Competition | Revenue pressure | Debt-free cannabis business |

---

#### 4. **Investor Takeaway**
Aurora Cannabis is at an **inflection point**, with **operational turnaround** evident in Q1 2026 results. However, the stock remains **highly speculative** due to regulatory risks and short-term losses. **Bullish case**: Long-term growth in the $5B+ global medical cannabis market . **Bearish case**: Ongoing legal uncertainties and high volatility.

**Final Verdict**: ACB is a **high-risk, high-reward** play for investors with a **long-term horizon** and tolerance for market swings.

---
**Sources**: